Cone L A, Woodard D R, Stoltzman D S, Byrd R G
Antimicrob Agents Chemother. 1985 Jul;28(1):33-6. doi: 10.1128/AAC.28.1.33.
A prospective, randomized study was undertaken to compare the efficacy and safety of ceftazidime with those of a combination of ticarcillin and tobramycin in the treatment of 40 nonneutropenic patients with pneumonia or bacteremia. Altogether, 93% of the patients receiving ceftazidime for pneumonia were cured, and 87% of those with bacteremia responded favorably. Of the subjects who were treated with ticarcillin and tobramycin ceftazidime developed significant superinfection, and one individual treated with the aminoglycoside and carboxypenicillin developed reversible azotemia. Ceftazidime appears to be as efficacious as the ticarcillin-tobramycin combination and is probably safer with regard to oto-and nephrotoxicity; however, superinfections did occur more frequently in the group treated with ceftazidime.
进行了一项前瞻性随机研究,以比较头孢他啶与替卡西林和妥布霉素联合用药在治疗40例非中性粒细胞减少的肺炎或菌血症患者中的疗效和安全性。接受头孢他啶治疗肺炎的患者中,共有93%治愈,菌血症患者中有87%反应良好。在接受替卡西林和妥布霉素治疗的患者中,头孢他啶出现了严重的二重感染,一名接受氨基糖苷类和羧苄青霉素治疗的患者出现了可逆性氮质血症。头孢他啶似乎与替卡西林-妥布霉素联合用药一样有效,并且在耳毒性和肾毒性方面可能更安全;然而,头孢他啶治疗组中二重感染的发生率确实更高。